TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03943212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Rate Reduction
Description: Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
Study: NCT02618304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Meibomian gland dysfunction
Description: artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
Study: NCT04634058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 antibody combined with CTLA-4 antibody
Description: After 4 cycles of PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
Study: NCT02615990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erigo Pro
Description: Verticalization table with two integrated robotic devices for leg movement and cyclic loading

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Patients receive standard physical therapy.
Study: NCT04469478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey and interview
Description: Patients and caregivers will provide information via surveys and interviews regarding their experience viewing diagnostic imaging using conventional methods and using Virtual Reality
Study: NCT02439125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl
Description: 2.5 mg b.i.d. orally for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl
Description: 5.0 mg b.i.d. orally for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl
Description: 7.5 mg b.i.d. orally for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: b.i.d. orally for 3 weeks
Study: NCT00526682

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Irvingia/cissus combo
Study: NCT01931358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Description: 1 mL intramuscular injection containing 10\^6 CCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Description: 1 mL intramuscular injection containing 10\^6 CCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Description: 1 mL intramuscular injection containing 10\^6 CCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Description: 1 mL intramuscular injection containing 10\^6 CCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV Placebo
Description: 1 mL per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV Placebo
Description: 1 mL per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV Placebo
Description: 1 mL per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV Placebo
Description: 1 mL per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E Placebo
Description: 1 mL per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E Placebo
Description: 1 mL per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E Placebo
Description: 1 mL per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E Placebo
Description: 1 mL per injection
Study: NCT00223496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
Study: NCT00781456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 91-day Levonorgestrel Oral Contraceptive
Description: 91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily to match experimental arm
Study: NCT00528762

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Focus group discussion about puberty and body image lasting 1 1/2 hours.
Study: NCT00488982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and GM-CSF
Description: Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
Study: NCT01414257

Intervention type: DRUG
Intervention: Methotrexate (MTX)
Description: Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
Study: NCT01673321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
Study: NCT00933049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Oral amoxicillin (25mg/kg/dose)for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole
Description: Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole placebo
Study: NCT04434274

Intervention type: DRUG
Intervention: Micronized Purified Flavonoid Fraction
Description: Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
Study: NCT03393273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: * Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~* melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~* Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21
Study: NCT02499432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement
Description: Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
Study: NCT00421668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: zinc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: zinc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: Vitamins C, E, B1, B2, niacin, B6, folate and B12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: Vitamins C, E, B1, B2, niacin, B6, folate and B12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00557219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam (Corlopam)
Description: continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketanserin (Sufrexal)
Description: continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
Study: NCT01726348

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
Study: NCT00424827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Fluorouracil with External Beam Radiation
Description: This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
Study: NCT02952222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients in Group DP will receive 0.5 mcg/kg Dexmedetomidine (DEX) administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of Bispectral Index (BIS) 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Group P)
Description: Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Group DP)
Description: Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
Study: NCT03756038

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
Study: NCT05409339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
Study: NCT00413361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: versus hydroxychloroquine
Description: versus hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: versus hydroxychloroquine
Description: versus hydroxychloroquine
Study: NCT03868683

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 1
Description: 30 g of glucose dissolved in 250 ml of water

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 2
Description: 30 g of glucose dissolved in 250 ml of water

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose reference 3
Description: 30 g of glucose dissolved in 250 ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 30 g of Sucrose dissolved in 250 ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Bake beans in tomato sauce
Description: Bake beans in tomato sauce containing 14 g of sugar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bake beans in tomato sauce, reduced sugar
Description: Bake beans in tomato sauce containing 12.2 g of sugar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bake beans in tomato sauce, low GI
Description: Bake beans in tomato sauce containing 7.2 g of sugar
Study: NCT02750462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Description: Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed/selective coronary angiography
Description: Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
Study: NCT03047070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: IV Lidocaine infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV normal saline infusion
Study: NCT02981771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance activity program
Description: Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Strength activity program
Description: Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
Study: NCT00637260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation on.
Description: The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: motor cortex stimulation off
Description: The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
Study: NCT00586573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine hydrochloride
Description: tablet, 5-20 mg, twice daily, by mouth, 12 weeks
Study: NCT02469090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: Use to treat up to 5 OFF episodes per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04564586

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DPPFit
Description: Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
Study: NCT00085371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study: NCT04329195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: discontinuation of RAS blocker therapy
Description: discontinuation of RAS blocker therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2: continuation of RAS blocker therapy
Description: continuation of RAS blocker therapy
Study: NCT02266693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
Study: NCT00525759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel
Description: 3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid
Description: 3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
Study: NCT04507659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Morning: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets; Evening: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Morning: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets; Evening: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.
Study: NCT00612443

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
Study: NCT01898182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetin, N6-furfuryladenine, 0.1%
Study: NCT00117468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2011
Description: Administered vaginally from Day 14 to Day 31

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 8% Vaginal Gel
Description: Administered vaginally from Cycle Day 14 to Day 31